TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05746442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Automated Messaging
Description: An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be provided with a 8 week supply of nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be provided with a 8 week supply of nicotine patches

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice to Quit and Smoking Cessation Self Help Materials
Description: Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice to Quit and Smoking Cessation Self Help Materials
Description: Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Assessment
Description: Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
Study: NCT05177536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide is a novel potent cereblon E3 ligase modulator
Study: NCT05716542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
Study: NCT06439602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 50 mg
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 75 mg
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Solid Oral Capsule Placebo
Study: NCT06269315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning product exposure
Description: Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
Study: NCT05300035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human monoclonal antibody (bNAbs)
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Study: NCT05674955

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circuit weight versus aerobic training
Description: Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circuit weight versus aerobic training
Description: Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circuit weight versus aerobic training
Description: Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C.
Study: NCT05696119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-PROTECT
Description: I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material.
Study: NCT06312176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal doxorubicin
Description: IV infusion
Study: NCT04649905

Intervention type: PROCEDURE
Intervention: Surgical Treatment
Description: Surgical standard-of-care treatment for knee OCD

Intervention type: PROCEDURE
Intervention: Nonoperative Treatment
Description: Nonoperative standard-of-care treatment for knee OCD
Study: NCT06571058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance
Description: Assist patient with walking approximately 90 feet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a short instructional session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a short instructional session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear the B3 Buddy device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Secure the urinary drainage bag to the patient using the B3 Buddy device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remove
Description: Remove the device and return urinary drainage bag to the standard position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walk approximately 90 feet
Study: NCT06122168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: verbal interview, standard health care, sheet of paper showing a mandala to be colored at will

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: verbal interview and standard health care
Study: NCT06368206

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational device Aktiia G2C
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as reference for blood pressure monitoring: double auscultation cuff
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff
Description: Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff
Description: Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed device used as reference for pulse rate monitoring: pulse finger oximeter
Description: Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
Study: NCT06323421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
Study: NCT06565143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial alternating current stimulation
Description: In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
Study: NCT04977960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Canrenoate
Description: potassium canrenoate for 7 days in addition to maximal medical treatment
Study: NCT04700007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Chloride
Description: Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
Study: NCT04838210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EleVATE Group Care
Description: 10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Prenatal Care
Description: The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
Study: NCT06165549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Light placebo therapy
Description: The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Emotion Bias Modification Training
Description: The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
Study: NCT04206059

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home sleep study
Description: Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (65db) up-slope of EEG with QST
Description: Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (65db) down-slope of EEG with QST
Description: 65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 db with QST
Description: sham stimulation (0 dB volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathe-Squeeze Task
Description: All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
Study: NCT04763668

Intervention type: OTHER
Intervention: Pregnant HIV positive women on ARTs
Description: Cardiovascular disease risk in pregnant HIV positive women on ARTs

Intervention type: OTHER
Intervention: Pregnant HIV positive women on ARTs
Description: Cardiovascular disease risk in pregnant HIV positive women on ARTs

Intervention type: OTHER
Intervention: Babies born to HIV positive mothers on ARTs
Description: cardiovascular disease risk in the offspring of HIV positive mothers on ARTs

Intervention type: OTHER
Intervention: Babies born to HIV positive mothers on ARTs
Description: cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
Study: NCT05991713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifying Exploration
Description: Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
Study: NCT06587204

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will receive standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentralized Group
Description: Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentralized Group
Description: Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentralized Group
Description: Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Literacy Navigation Group
Description: Participants will receive a one time digital literacy training virtual learning digital health education for the rest of the intervention . The digital literacy training is a digital health education program that will be given 1 hour a day for 3 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Literacy Navigation Group
Description: Participants will receive a one time digital literacy training virtual learning digital health education for the rest of the intervention . The digital literacy training is a digital health education program that will be given 1 hour a day for 3 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Care Navigation Group
Description: Participants will receive a one time social care navigation application that will be used for the rest of the intervention. The Social Care Navigation application is a digital application that provides social care resources in the community to participants. The application is used 1 hour a day, each day.
Study: NCT06589440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-8541A
Description: SR-8541A administered orally in combination with intravenous botensilimab and balstilimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-8541A
Description: SR-8541A administered orally in combination with intravenous botensilimab and balstilimab
Study: NCT06595953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze-Contingent Music Reward Therapy
Description: All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gaze-Contingent Music Reward Therapy
Description: All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
Study: NCT06601179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: high-intensity focused ultrasound treatment of benign prostatic hyperplasia